| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human ANGPTL7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于ANGPTL7抗体的文献概览(文献标题及摘要内容为模拟创作，仅供参考)：
1. **"ANGPTL7 Antibody Inhibits Ocular Fibrosis in a Mouse Model"**
*作者：Rashid S, et al.*
摘要：研究利用特异性ANGPTL7抗体靶向抑制TGF-β信号通路，发现其在小鼠模型中显著降低角膜纤维化程度，提示ANGPTL7抗体在治疗眼部纤维化疾病中的潜力。
2. **"Monoclonal Antibody Targeting ANGPTL7 Reduces Intraocular Pressure in Glaucoma"**
*作者：Zhang Y, et al.*
摘要：通过开发高亲和力ANGPTL7单克隆抗体，研究证实其可调节小梁网细胞外基质重塑，降低实验性青光眼动物模型的眼内压，为抗体疗法提供新方向。
3. **"ANGPTL7 as a Novel Biomarker in Tumor Angiogenesis: Antibody-Based Detection and Functional Analysis"**
*作者：Jian Liu, et al.*
摘要：研究利用ANGPTL7多克隆抗体进行免疫组化分析，揭示其在多种实体瘤血管内皮细胞中的高表达，并证明抗体阻断可抑制血管生成和肿瘤生长。
注：以上内容为示例性概括，实际文献需通过PubMed、Google Scholar等平台检索确认。
ANGPTL7 (Angiopoietin-like protein 7) is a secreted glycoprotein belonging to the angiopoietin-like family, which regulates lipid metabolism, angiogenesis, and tissue remodeling. Structurally, it contains an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain. Primarily expressed in the eyes, skeletal muscle, and connective tissues, ANGPTL7 has been linked to ocular diseases, particularly glaucoma, due to its role in extracellular matrix (ECM) remodeling and intraocular pressure regulation. It interacts with integrins and modulates TGF-β signaling, influencing cell adhesion, fibrosis, and trabecular meshwork dysfunction.
ANTGPTL7 antibodies are tools for detecting and studying this protein’s expression, localization, and function in both physiological and pathological contexts. Research suggests that neutralizing ANGPTL7 antibodies could mitigate ECM deposition in glaucoma or fibrosis-related diseases. In oncology, ANGPTL7 is studied for its potential role in tumor angiogenesis and metastasis, with antibodies aiding in biomarker discovery or therapeutic targeting. While preclinical studies show promise, clinical applications remain exploratory. Current efforts focus on optimizing antibody specificity and evaluating therapeutic potential in models of fibrosis, ocular hypertension, and cancer.
×
